- Cardiomyopathies are disorders that impair the function of the heart, and many cases are genetic in origin.
- Experts are exploring using gene therapies to treat cardiomyopathies.
- A research team called CureHeart recently received a £30 million grant from the British Heart Foundation to fuel further research in genetic medical treatments to help those with cardiomyopathies.
- The researchers will work on developing an injectable cure that works by silencing or altering certain genes.
Heart disease can take many forms and develop based on components like genetics, environmental factors, and lifestyle. Disorders that impact the muscles of the heart, or cardiomyopathies, can have genetic origins, which has fueled research about possible genetic treatments to cure them.
The research team
People with cardiomyopathy can experience a variety of symptoms ranging from mild to severe. There are several
Dr. Edo Paz, cardiologist and vice president of medical at digital care app K Health, who is not affiliated with CureHeart, explained to Medical News Today:
“Cardiomyopathies are diseases of the heart muscle. They can be extremely serious, as patients can develop congestive heart failure and irregular heart rhythms that can cause sudden cardiac death. There are many different types of cardiomyopathies, and treatment varies based on the type and/or cause.”
Dr. Paz also touched on current treatments.
“[I]n most cases of cardiomyopathy, there are a number of medications which can improve patient symptoms, improve or prevent worsening of heart muscle function, and improve survival. Other treatments that may apply to certain cardiomyopathies include surgery and/or placement of an implantable cardioverter-defibrillator. In severe cases, patients may undergo cardiac transplantation,” he said.
Sometimes, cardiomyopathy may have a genetic origin. When doctors know someone has specific gene variants associated with the disease, they can be proactive about monitoring and treatment options. However, unlocking the genetic causes of cardiomyopathy might also be the key to developing new treatments.
As part of its efforts to further the treatment of heart disease, the BHF organizes the global competition, the Big Beat Challenge. Different cardiology research teams vie at the chance to win £30 million to fund their research, presenting their ideas to a patient and public panel, and to a panel of researchers and medical professionals. The final decision was made by an international advisory panel that included leading figures in science and medicine.
The winner of the Big Beat Challenge was the research team,
They explain on their website that their aim is “to develop genetic therapies that precisely correct the faulty genes in the heart itself, thus providing a new treatment for, and ultimately curing, cardiomyopathies.”
“About 1 in every 250 people is affected by genetic heart muscle diseases, collectively called cardiomyopathy. Approximately 260,000 people in the U.K., and 1.5 million in the U.S., are affected; many are unaware that they may be at risk.”
— CureHeart team researchers
The researchers want to focus their efforts on correcting and switching off the genes that contribute to cardiomyopathies.
As part of their work, they have identified cardiomyopathy disease genes and how they cause cardiomyopathy. They have also worked on how to deliver genetic medicine so that it reaches the target of the heart muscle cells.
The CureHeart team is excited about how their research could help those with genetic cardiomyopathies. Still, they also note their research may expand to other areas, such as treatment for heart failure. They note that genetics can play a role in heart failure, and addressing the genetic root cause could be highly beneficial.
Developing cures for cardiomyopathies could impact the lives of many, including children affected by cardiomyopathies.
“Once successful, the same gene editing innovations could be used to treat a whole range of common heart conditions where genetic faults play a major role. This would have a transformational impact and offer hope to the thousands of families worldwide affected by these devastating diseases,” he says.
“This is a defining moment for cardiovascular medicine. Not only could CureHeart be the creators of the first cure for inherited heart muscle diseases by tackling killer genes that run through family trees, it could also usher in a new era of precision cardiology.”
— Prof. Sir Nilesh
Prof. Hugh Watkins, leading member of the CureHeart research team and professor of cardiovascular medicine at the British Heart Foundation, said he was excited about the funding and research development in this area.
“I am excited by the BHF’s Big Beat Challenge because the scale of the award made it possible to bring on board some truly world-class scientists including some who weren’t previously working on heart disease,” he told MNT.
“We think we have everything we need now to discover how to best use genetic therapies to fix the fundamental problem in inherited heart muscle diseases and begin to create cures where none exist at present,” he added.